Besides, the high score indicated higher sensitivity to immune checkpoint inhibitors.<h4>Conclusions</h4>We first developed and validated a TGF-β risk signature that could predict the clinical prognosis and TME immune features for GBM. The gene discussed is TGFB1; the disease is glioblastoma.